Form 4 for MYGN MYRIAD GENETICS INC
Accepted 2025-06-02 00:00:00 ET · period of report 2025-05-31 · accession 0001738340-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-06-02 | 2025-05-31 | MYGN | Raha Samraat S. | Pres, CEO, Dir | A - Grant | $3.56 | +1,498 | 482.7K | +0.3% | +$5,333 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-31 | A | A | 1,498 | $3.56 | 482,738 | D | — | — | (F1) These shares were acquired under the Myriad Genetics, Inc. Amended and Restated 2012 Employee Stock Purchase Plan, in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c). |